Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment
The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.
Read more on NPR
August 8, 2019 at 04:00PM
Health Care
Thứ Năm, 8 tháng 8, 2019
Đăng ký:
Đăng Nhận xét (Atom)
0 nhận xét:
Đăng nhận xét